NASDAQ:MTVA MetaVia (MTVA) Stock Price, News & Analysis $1.09 -0.24 (-18.05%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$1.11 +0.02 (+2.02%) As of 05/8/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MetaVia Stock (NASDAQ:MTVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MetaVia alerts:Sign Up Key Stats Today's Range$1.00▼$1.3350-Day Range$1.17▼$1.6352-Week Range$1.00▼$19.03Volume482,185 shsAverage Volume153,282 shsMarket Capitalization$5.62 millionP/E RatioN/ADividend YieldN/APrice Target$26.50Consensus RatingHold Company Overview MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass. Read More MetaVia Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreMTVA MarketRank™: MetaVia scored higher than 40% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingMetaVia has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMetaVia has a consensus price target of $26.50, representing about 2,331.2% upside from its current price of $1.09.Amount of Analyst CoverageMetaVia has only been the subject of 2 research reports in the past 90 days.Read more about MetaVia's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MetaVia are expected to decrease in the coming year, from ($2.72) to ($3.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MetaVia is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MetaVia is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMetaVia has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about MetaVia's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.25% of the float of MetaVia has been sold short.Short Interest Ratio / Days to CoverMetaVia has a short interest ratio ("days to cover") of 0.45, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MetaVia has recently increased by 13.29%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMetaVia does not currently pay a dividend.Dividend GrowthMetaVia does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest1 people have searched for MTVA on MarketBeat in the last 30 days. MarketBeat Follows6 people have added MetaVia to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MetaVia insiders have not sold or bought any company stock.Percentage Held by Insiders0.80% of the stock of MetaVia is held by insiders.Percentage Held by Institutions1.37% of the stock of MetaVia is held by institutions.Read more about MetaVia's insider trading history. Receive MTVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MetaVia and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MTVA Stock News HeadlinesMetaVia (MTVA) price target decreased by 71.04% to 19.72April 29, 2026 | msn.comMetaVia Stock Dividends | NASDAQ:MTVA | BenzingaApril 28, 2026 | benzinga.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 9 at 1:00 AM | Paradigm Press (Ad)MetaVia Inc.: MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of ObesityApril 10, 2026 | finanznachrichten.deMetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of ObesityApril 10, 2026 | prnewswire.comMetaVia (MTVA) price target decreased by 15.51% to 68.08April 9, 2026 | msn.comMetaVia Inc.April 7, 2026 | edition.cnn.comMTVA: Phase 1 Part 3 16-Week Titration Study of DA-1726 to Initiate in April 2026…March 31, 2026 | finance.yahoo.comSee More Headlines MTVA Stock Analysis - Frequently Asked Questions How have MTVA shares performed this year? MetaVia's stock was trading at $8.42 at the beginning of the year. Since then, MTVA shares have decreased by 87.1% and is now trading at $1.09. How were MetaVia's earnings last quarter? MetaVia Inc. (NASDAQ:MTVA) issued its earnings results on Thursday, November, 6th. The company reported ($1.54) earnings per share for the quarter, topping the consensus estimate of ($2.86) by $1.32. When did MetaVia's stock split? MetaVia's stock reverse split on the morning of Friday, December 5th 2025.The 1-11 reverse split was announced on Tuesday, December 2nd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. When did MetaVia IPO? MetaVia (MTVA) raised $36 million in an initial public offering on Thursday, June 23rd 2016. The company issued 3,000,000 shares at a price of $11.00-$13.00 per share. How do I buy shares of MetaVia? Shares of MTVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/06/2025Today5/09/2026Next Earnings (Estimated)5/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 MTVA's financial health is in the Red zone, according to TradeSmith. MTVA has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MTVA Previous SymbolNASDAQ:NRBO CIK1638287 Webwww.neurobopharma.com Phone857-702-9600Fax734-293-0444Employees8Year FoundedN/APrice Target and Rating Average Price Target for MetaVia$26.50 High Price Target$33.00 Low Price Target$20.00 Potential Upside/Downside+2,331.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($8.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-202.17% Return on Assets-91.89% Debt Debt-to-Equity RatioN/A Current Ratio1.93 Quick Ratio1.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book0.47Miscellaneous Outstanding Shares5,160,000Free Float5,123,000Market Cap$5.62 million OptionableN/A Beta0.59 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:MTVA) was last updated on 5/9/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
